KetamineOne Capital Limited (“Ketamine One” or the
“Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a
company focused on consolidating medical clinics and becoming a
North American leader in mental health treatments, is pleased to
announce that its wholly-owned subsidiary, Integrated Rehab and
Performance Ltd., is expanding its business through the addition of
four new, veteran-focused, multidisciplinary clinics in the Comox
Valley, Ottawa, Halifax and Surrey (the “
New
Clinics”). The Comox Valley location is scheduled to begin
offering programs on September 6, 2021 and the Ottawa location is
also expected to be opened in the month of September. The Halifax
and Surrey centres are expected to be opened by the end of
December.
In addition, the Company announces that
Integrated Rehab and Performance Ltd. has been re-branded as IRP
Health Ltd. (“IRP” or the
“Subsidiary”) to better reflect its planned
evolution into more of a multidisciplinary business as part of
Ketamine One while also preserving its roots. IRP has successfully
performed over 10,000 unique treatments for past or present
personnel of the Canadian Armed Forces and the Royal Canadian
Mounted Police, as well as first responders including firefighters,
law enforcement officers, paramedics and emergency medical
technicians.
As Canada’s only set of physical rehabilitation
clinics exclusively treating members of the veteran and first
responder patient population, IRP fills a critical role in
providing customized treatment programs and is seeing strong demand
for its services. There is a growing need for mental and physical
health services for Canada’s first responders and Ketamine One will
strive to continue being the leader in providing customized
treatments through the expansion of IRP locations and services.
Ketamine One and IRP have identified locations
with high concentration of veterans and communities with ties to
the military. Current Ketamine One clinics in Ottawa and Halifax
will be retrofitted and rebranded as IRP Health clinics. The Ottawa
clinic will be located at #305 1385 Bank Street, in an area that
has a local population of over 9,000 veterans. The Comox Valley
location will be located at 780 30th Street in Courtenay, BC. The
Comox Valley is one of the top retirement destinations in Canada
for military veterans.
Towards the end of 2021, the Halifax and Surrey
centres are planning to be operational after short construction
periods for each. The Halifax area currently has more than 14,000
veterans in the local area. Lastly, the Surrey facility is expected
to be located at #204 13737 96th Avenue, which will be in
association with the neuroplasticity clinic within the innovation
hub in the Health and Technology District.
Additionally, Dr. Dennis Filips has signed his
agreement to provide assessment and consultation services for IRP’s
flagship programs in Ottawa, as well as to advocate and raise
awareness of IRP’s services in the veteran and health communities.
As a recently announced member of Ketamine One’s Medical Advisory
Board, Dr. Dennis Filips is the principal founder and Chief Medical
Officer of Innovative Trauma Care. He is a trauma surgeon who
retired from the Canadian Forces after 20 years of service and
completing tours in Afghanistan, Bosnia, and the Golan Heights.
Dennis has also worked as a course director for Tactical Medicine
courses for the military and tactical police units, among other
roles and accomplishments throughout his career to date.
Management Commentary
“The re-brand to IRP Health is a great milestone
for this business as we prepare to expand our footprint across
Canada and potentially beyond. I look forward to bringing our
patient-specific treatment plans and innovative technological tools
involving digital therapeutics to more locales, as we continue
helping to heal more veterans and first responders during these
anxious times,” said Steven Inglefield, Founder and CEO of IRP.
“We can see first-hand, the enormous need for
increased physical and mental health services for the veteran and
first responder communities in Canada. Ketamine One is committed to
making innovative treatments available and including veterans’
health as a foundational aspect of our network. We identified IRP
as having a unique and scalable model that complemented our other
clinics and positioned us to have a leading position in advancing
the health of members of the military, first responders and
veterans. The Ketamine One team is excited to grow our locations
and treatment programs in both Canada and the U.S.,” added Adam
Deffett, Interim CEO of Ketamine One.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic
Capital Corp.) is a company focused on consolidating medical
clinics and becoming a North American leader in mental health
treatments. It is working to provide the critical infrastructure
needed to develop and deliver breakthrough mental health
treatments. Currently, Ketamine One has a network of 16 clinics
across North America, with plans to further consolidate the highly
fragmented industry. The recent addition of KGK Science Inc. as the
Company’s contract research division also places the company at the
forefront of premium clinical research based on its 24-year history
and extensive experience in pharmaceuticals, cannabis, and the
emerging psychedelic medicine industries. As a collective
enterprise, Ketamine One is dedicated to helping solve the growing
need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Adam Deffett"Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor RelationsTel:
1-844-PHONE-K1 (1-844-746-6351)Email: IR@ketamine.one Web:
www.ketamine.one Twitter: @KetamineOne
Notice Regarding Forward-Looking
Information:
This news release contains forward-looking
statements including but not limited to statements regarding the
Company’s business, assets or investments, as well other statements
that are not historical facts. Readers are cautioned not to place
undue reliance on forward-looking statements, as there can be no
assurance that the plans, intentions or expectations upon which
they are based will occur. By their nature, forward-looking
statements involve numerous assumptions, known and unknown risks
and uncertainties, both general and specific, that contribute to
the possibility that the predictions, forecasts, projections and
other forward-looking statements will not occur, which may cause
actual performance and results in future periods to differ
materially from any estimates or projections of future performance
or results expressed or implied by such forward-looking statements.
These assumptions, risks and uncertainties include, among other
things, the state of the economy in general and capital markets in
particular, investor interest in the business and future prospects
of the Company.
The forward-looking statements contained in this
news release are made as of the date of this news release. Except
as required by law, the Company disclaims any intention and assumes
no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable securities law. Additionally, the
Company undertakes no obligation to comment on the expectations of,
or statements made, by third parties in respect of the matters
discussed above.
Myconic Capital (TSXV:MEDI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Myconic Capital (TSXV:MEDI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024